Abstract: Venetoclax is the first highly selective inhibitor of oral B-cell lymphoma 2 (Bcl-2) to be approved. It is characterized by its unique function of targeting the apoptotic pathway of tumor cells with high affinity. Venetoclax has received approval from the U.S. Food and Drug Administration for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) and newly diagnosed acute myeloid leukemia (AML) who are not suitable for aggressive induction chemotherapy or those aged>75 years. In recent years, venetoclax has shown superiority in the treatment of acute lymphoblastic leukemia (ALL). Patients with special subtypes of ALL, such as early T-cell precursor ALL (ETP-ALL) and other relapsed/refractory forms of ALL (R/R ALL), who do not respond well to conventional chemotherapy regimens can achieve increased rates of complete response (CR) and long-term survival on receiving venetoclax combined with chemotherapy or other targeted therapies. In addition, the combined use of venetoclax and tyrosine kinase inhibitors(TKI) has demonstrated favorable outcomes in patients with Philadelphia-chromosome positive ALL (Ph⁺ALL), suggesting the great potential of venetoclax in the treatment of ALL. In this review, we summarized the role of venetoclax in the treatment of ALL and research progress in this field.